EdenTree’s Patel: Investors should question Pfizer’s M&A strategy

The $14 billion (£11 billion) takeover of US biotech Medivation by Pfizer has aroused the question among long-term investors as to whether management have overpaid for the company. Ketan Patel fund manager at EdenTree Investment Management discusses with Fund Strategy.

Link

top